Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review. Part 2 - Radiological features and metric markers.

Fiche publication

Date publication

janvier 2021

Journal

Critical reviews in oncology/hematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine , Pr NOEL Georges , Dr SCHOTT Roland , Mme CHAMBRELANT Isabelle , Dr CEBULA Hélène , Dr LE FEVRE Clara , Dr BUND Caroline

Tous les auteurs :
Le Fèvre C, Constans JM, Chambrelant I, Antoni D, Bund C, Leroy-Freschini B, Schott R, Cebula H, Noël G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33515701

Résumé

After chemoradiotherapy for glioblastoma, pseudoprogression can occur and must be distinguished from true progression to correctly manage glioblastoma treatment and follow-up. Conventional treatment response assessment is evaluated via conventional MRI (contrast-enhanced T1-weighted and T2/FLAIR), which is unreliable. The emergence of advanced MRI techniques, MR spectroscopy, and PET tracers has improved pseudoprogression diagnostic accuracy. This review presents a literature review of the different imaging techniques and potential imaging biomarkers to differentiate pseudoprogression from true progression.